nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—PDE4C—brainstem—multiple sclerosis	0.00905	0.158	CbGeAlD
Roflumilast—PDE4C—midbrain—multiple sclerosis	0.00577	0.1	CbGeAlD
Roflumilast—PDE4C—nervous system—multiple sclerosis	0.00474	0.0825	CbGeAlD
Roflumilast—PDE4C—central nervous system—multiple sclerosis	0.00456	0.0795	CbGeAlD
Roflumilast—PDE4D—cerebellum—multiple sclerosis	0.00393	0.0684	CbGeAlD
Roflumilast—PDE4C—brain—multiple sclerosis	0.00362	0.0631	CbGeAlD
Roflumilast—PDE4A—cerebellum—multiple sclerosis	0.00348	0.0605	CbGeAlD
Roflumilast—PDE4D—brain—multiple sclerosis	0.00319	0.0555	CbGeAlD
Roflumilast—PDE4B—medulla oblongata—multiple sclerosis	0.00293	0.051	CbGeAlD
Roflumilast—PDE4A—brain—multiple sclerosis	0.00282	0.0491	CbGeAlD
Roflumilast—Hypersensitivity—Cladribine—multiple sclerosis	0.00268	0.00295	CcSEcCtD
Roflumilast—PDE4B—midbrain—multiple sclerosis	0.00268	0.0466	CbGeAlD
Roflumilast—Malaise—Mitoxantrone—multiple sclerosis	0.00264	0.00291	CcSEcCtD
Roflumilast—Renal failure acute—Methotrexate—multiple sclerosis	0.00262	0.00289	CcSEcCtD
Roflumilast—PDE4B—spinal cord—multiple sclerosis	0.00261	0.0455	CbGeAlD
Roflumilast—Asthenia—Cladribine—multiple sclerosis	0.00261	0.00287	CcSEcCtD
Roflumilast—Weight decreased—Betamethasone—multiple sclerosis	0.0026	0.00286	CcSEcCtD
Roflumilast—Weight decreased—Dexamethasone—multiple sclerosis	0.0026	0.00286	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00255	0.00281	CcSEcCtD
Roflumilast—Rhinitis—Triamcinolone—multiple sclerosis	0.00254	0.0028	CcSEcCtD
Roflumilast—Rhinitis—Methylprednisolone—multiple sclerosis	0.00254	0.00279	CcSEcCtD
Roflumilast—Myalgia—Mitoxantrone—multiple sclerosis	0.00249	0.00274	CcSEcCtD
Roflumilast—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.00249	0.00274	CcSEcCtD
Roflumilast—Diarrhoea—Cladribine—multiple sclerosis	0.00249	0.00274	CcSEcCtD
Roflumilast—Anxiety—Mitoxantrone—multiple sclerosis	0.00248	0.00273	CcSEcCtD
Roflumilast—Discomfort—Mitoxantrone—multiple sclerosis	0.00246	0.00271	CcSEcCtD
Roflumilast—Feeling abnormal—Azathioprine—multiple sclerosis	0.00244	0.00268	CcSEcCtD
Roflumilast—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.00242	0.00266	CcSEcCtD
Roflumilast—Dizziness—Cladribine—multiple sclerosis	0.0024	0.00265	CcSEcCtD
Roflumilast—Infection—Mitoxantrone—multiple sclerosis	0.00237	0.00261	CcSEcCtD
Roflumilast—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.00235	0.00259	CcSEcCtD
Roflumilast—Abdominal pain—Azathioprine—multiple sclerosis	0.00234	0.00257	CcSEcCtD
Roflumilast—Skin disorder—Mitoxantrone—multiple sclerosis	0.00232	0.00255	CcSEcCtD
Roflumilast—Vomiting—Cladribine—multiple sclerosis	0.00231	0.00254	CcSEcCtD
Roflumilast—Rash—Cladribine—multiple sclerosis	0.00229	0.00252	CcSEcCtD
Roflumilast—Dermatitis—Cladribine—multiple sclerosis	0.00229	0.00252	CcSEcCtD
Roflumilast—Immune system disorder—Methylprednisolone—multiple sclerosis	0.00229	0.00252	CcSEcCtD
Roflumilast—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.00228	0.00251	CcSEcCtD
Roflumilast—Headache—Cladribine—multiple sclerosis	0.00228	0.00251	CcSEcCtD
Roflumilast—Weight decreased—Prednisone—multiple sclerosis	0.00227	0.00249	CcSEcCtD
Roflumilast—Ill-defined disorder—Prednisolone—multiple sclerosis	0.00223	0.00245	CcSEcCtD
Roflumilast—Depression—Prednisone—multiple sclerosis	0.00223	0.00245	CcSEcCtD
Roflumilast—Mental disorder—Methylprednisolone—multiple sclerosis	0.00222	0.00244	CcSEcCtD
Roflumilast—Malnutrition—Methylprednisolone—multiple sclerosis	0.0022	0.00243	CcSEcCtD
Roflumilast—PDE4B—nervous system—multiple sclerosis	0.0022	0.0383	CbGeAlD
Roflumilast—Angioedema—Prednisolone—multiple sclerosis	0.0022	0.00242	CcSEcCtD
Roflumilast—Hypersensitivity—Azathioprine—multiple sclerosis	0.00218	0.0024	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.00218	0.0024	CcSEcCtD
Roflumilast—Malaise—Prednisolone—multiple sclerosis	0.00217	0.00238	CcSEcCtD
Roflumilast—Dysgeusia—Triamcinolone—multiple sclerosis	0.00216	0.00238	CcSEcCtD
Roflumilast—Nausea—Cladribine—multiple sclerosis	0.00216	0.00238	CcSEcCtD
Roflumilast—Vertigo—Prednisolone—multiple sclerosis	0.00216	0.00238	CcSEcCtD
Roflumilast—Back pain—Triamcinolone—multiple sclerosis	0.00214	0.00235	CcSEcCtD
Roflumilast—PDE4B—central nervous system—multiple sclerosis	0.00212	0.0369	CbGeAlD
Roflumilast—Dyspepsia—Mitoxantrone—multiple sclerosis	0.0021	0.00232	CcSEcCtD
Roflumilast—Decreased appetite—Mitoxantrone—multiple sclerosis	0.00208	0.00229	CcSEcCtD
Roflumilast—PDE4B—cerebellum—multiple sclerosis	0.00207	0.0361	CbGeAlD
Roflumilast—Fatigue—Mitoxantrone—multiple sclerosis	0.00206	0.00227	CcSEcCtD
Roflumilast—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00205	0.00226	CcSEcCtD
Roflumilast—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.00205	0.00225	CcSEcCtD
Roflumilast—Constipation—Mitoxantrone—multiple sclerosis	0.00204	0.00225	CcSEcCtD
Roflumilast—Diarrhoea—Azathioprine—multiple sclerosis	0.00202	0.00223	CcSEcCtD
Roflumilast—Discomfort—Prednisolone—multiple sclerosis	0.00202	0.00222	CcSEcCtD
Roflumilast—Angioedema—Triamcinolone—multiple sclerosis	0.00202	0.00222	CcSEcCtD
Roflumilast—Angioedema—Methylprednisolone—multiple sclerosis	0.00201	0.00222	CcSEcCtD
Roflumilast—Malaise—Triamcinolone—multiple sclerosis	0.00199	0.00219	CcSEcCtD
Roflumilast—Malaise—Methylprednisolone—multiple sclerosis	0.00199	0.00219	CcSEcCtD
Roflumilast—Vertigo—Triamcinolone—multiple sclerosis	0.00199	0.00218	CcSEcCtD
Roflumilast—Vertigo—Methylprednisolone—multiple sclerosis	0.00198	0.00218	CcSEcCtD
Roflumilast—Connective tissue disorder—Prednisone—multiple sclerosis	0.00197	0.00217	CcSEcCtD
Roflumilast—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00197	0.00217	CcSEcCtD
Roflumilast—Dizziness—Azathioprine—multiple sclerosis	0.00196	0.00215	CcSEcCtD
Roflumilast—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00195	0.00215	CcSEcCtD
Roflumilast—Urticaria—Mitoxantrone—multiple sclerosis	0.0019	0.00209	CcSEcCtD
Roflumilast—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00189	0.00208	CcSEcCtD
Roflumilast—Myalgia—Triamcinolone—multiple sclerosis	0.00188	0.00207	CcSEcCtD
Roflumilast—Vomiting—Azathioprine—multiple sclerosis	0.00188	0.00207	CcSEcCtD
Roflumilast—Pneumonia—Methotrexate—multiple sclerosis	0.00188	0.00207	CcSEcCtD
Roflumilast—Myalgia—Methylprednisolone—multiple sclerosis	0.00188	0.00207	CcSEcCtD
Roflumilast—Anxiety—Methylprednisolone—multiple sclerosis	0.00187	0.00206	CcSEcCtD
Roflumilast—Infestation NOS—Methotrexate—multiple sclerosis	0.00187	0.00205	CcSEcCtD
Roflumilast—Infestation—Methotrexate—multiple sclerosis	0.00187	0.00205	CcSEcCtD
Roflumilast—Rash—Azathioprine—multiple sclerosis	0.00186	0.00205	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00186	0.00205	CcSEcCtD
Roflumilast—Dermatitis—Azathioprine—multiple sclerosis	0.00186	0.00205	CcSEcCtD
Roflumilast—Depression—Methotrexate—multiple sclerosis	0.00186	0.00205	CcSEcCtD
Roflumilast—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.00186	0.00205	CcSEcCtD
Roflumilast—Ill-defined disorder—Betamethasone—multiple sclerosis	0.00186	0.00205	CcSEcCtD
Roflumilast—Discomfort—Triamcinolone—multiple sclerosis	0.00186	0.00205	CcSEcCtD
Roflumilast—Discomfort—Methylprednisolone—multiple sclerosis	0.00185	0.00204	CcSEcCtD
Roflumilast—Headache—Azathioprine—multiple sclerosis	0.00185	0.00204	CcSEcCtD
Roflumilast—Angioedema—Dexamethasone—multiple sclerosis	0.00183	0.00202	CcSEcCtD
Roflumilast—Angioedema—Betamethasone—multiple sclerosis	0.00183	0.00202	CcSEcCtD
Roflumilast—Immune system disorder—Prednisone—multiple sclerosis	0.00181	0.00199	CcSEcCtD
Roflumilast—Malaise—Betamethasone—multiple sclerosis	0.00181	0.00199	CcSEcCtD
Roflumilast—Malaise—Dexamethasone—multiple sclerosis	0.00181	0.00199	CcSEcCtD
Roflumilast—Vertigo—Dexamethasone—multiple sclerosis	0.0018	0.00198	CcSEcCtD
Roflumilast—Vertigo—Betamethasone—multiple sclerosis	0.0018	0.00198	CcSEcCtD
Roflumilast—Infection—Triamcinolone—multiple sclerosis	0.00179	0.00197	CcSEcCtD
Roflumilast—Infection—Methylprednisolone—multiple sclerosis	0.00179	0.00197	CcSEcCtD
Roflumilast—Insomnia—Prednisolone—multiple sclerosis	0.00177	0.00195	CcSEcCtD
Roflumilast—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00177	0.00194	CcSEcCtD
Roflumilast—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00176	0.00194	CcSEcCtD
Roflumilast—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00176	0.00194	CcSEcCtD
Roflumilast—Mental disorder—Prednisone—multiple sclerosis	0.00176	0.00193	CcSEcCtD
Roflumilast—Nausea—Azathioprine—multiple sclerosis	0.00176	0.00193	CcSEcCtD
Roflumilast—Skin disorder—Methylprednisolone—multiple sclerosis	0.00175	0.00192	CcSEcCtD
Roflumilast—Malnutrition—Prednisone—multiple sclerosis	0.00175	0.00192	CcSEcCtD
Roflumilast—Asthenia—Mitoxantrone—multiple sclerosis	0.00171	0.00189	CcSEcCtD
Roflumilast—Myalgia—Betamethasone—multiple sclerosis	0.00171	0.00188	CcSEcCtD
Roflumilast—Myalgia—Dexamethasone—multiple sclerosis	0.00171	0.00188	CcSEcCtD
Roflumilast—Anxiety—Dexamethasone—multiple sclerosis	0.0017	0.00187	CcSEcCtD
Roflumilast—Anxiety—Betamethasone—multiple sclerosis	0.0017	0.00187	CcSEcCtD
Roflumilast—Discomfort—Dexamethasone—multiple sclerosis	0.00169	0.00186	CcSEcCtD
Roflumilast—Discomfort—Betamethasone—multiple sclerosis	0.00169	0.00186	CcSEcCtD
Roflumilast—PDE4B—brain—multiple sclerosis	0.00168	0.0293	CbGeAlD
Roflumilast—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00164	0.00181	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00164	0.0018	CcSEcCtD
Roflumilast—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00164	0.0018	CcSEcCtD
Roflumilast—Insomnia—Triamcinolone—multiple sclerosis	0.00163	0.00179	CcSEcCtD
Roflumilast—Insomnia—Methylprednisolone—multiple sclerosis	0.00163	0.00179	CcSEcCtD
Roflumilast—Infection—Dexamethasone—multiple sclerosis	0.00163	0.00179	CcSEcCtD
Roflumilast—Infection—Betamethasone—multiple sclerosis	0.00163	0.00179	CcSEcCtD
Roflumilast—Ill-defined disorder—Prednisone—multiple sclerosis	0.00162	0.00178	CcSEcCtD
Roflumilast—Feeling abnormal—Prednisolone—multiple sclerosis	0.00162	0.00178	CcSEcCtD
Roflumilast—Nervous system disorder—Dexamethasone—multiple sclerosis	0.0016	0.00177	CcSEcCtD
Roflumilast—Nervous system disorder—Betamethasone—multiple sclerosis	0.0016	0.00177	CcSEcCtD
Roflumilast—Angioedema—Prednisone—multiple sclerosis	0.0016	0.00176	CcSEcCtD
Roflumilast—Dyspepsia—Triamcinolone—multiple sclerosis	0.00159	0.00175	CcSEcCtD
Roflumilast—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00158	0.00174	CcSEcCtD
Roflumilast—Malaise—Prednisone—multiple sclerosis	0.00157	0.00173	CcSEcCtD
Roflumilast—Vertigo—Prednisone—multiple sclerosis	0.00157	0.00173	CcSEcCtD
Roflumilast—Urticaria—Prednisolone—multiple sclerosis	0.00156	0.00171	CcSEcCtD
Roflumilast—Cardiac disorder—Methotrexate—multiple sclerosis	0.00156	0.00171	CcSEcCtD
Roflumilast—Fatigue—Triamcinolone—multiple sclerosis	0.00155	0.00171	CcSEcCtD
Roflumilast—Fatigue—Methylprednisolone—multiple sclerosis	0.00155	0.00171	CcSEcCtD
Roflumilast—Vomiting—Mitoxantrone—multiple sclerosis	0.00152	0.00167	CcSEcCtD
Roflumilast—Immune system disorder—Methotrexate—multiple sclerosis	0.00151	0.00167	CcSEcCtD
Roflumilast—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00151	0.00166	CcSEcCtD
Roflumilast—Rash—Mitoxantrone—multiple sclerosis	0.00151	0.00166	CcSEcCtD
Roflumilast—Dermatitis—Mitoxantrone—multiple sclerosis	0.00151	0.00166	CcSEcCtD
Roflumilast—Headache—Mitoxantrone—multiple sclerosis	0.0015	0.00165	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.00149	0.00164	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.00149	0.00164	CcSEcCtD
Roflumilast—Myalgia—Prednisone—multiple sclerosis	0.00149	0.00164	CcSEcCtD
Roflumilast—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00149	0.00164	CcSEcCtD
Roflumilast—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00148	0.00163	CcSEcCtD
Roflumilast—Anxiety—Prednisone—multiple sclerosis	0.00148	0.00163	CcSEcCtD
Roflumilast—Insomnia—Betamethasone—multiple sclerosis	0.00148	0.00163	CcSEcCtD
Roflumilast—Insomnia—Dexamethasone—multiple sclerosis	0.00148	0.00163	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00148	0.00162	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00147	0.00162	CcSEcCtD
Roflumilast—Discomfort—Prednisone—multiple sclerosis	0.00147	0.00162	CcSEcCtD
Roflumilast—Mental disorder—Methotrexate—multiple sclerosis	0.00147	0.00162	CcSEcCtD
Roflumilast—Malnutrition—Methotrexate—multiple sclerosis	0.00146	0.00161	CcSEcCtD
Roflumilast—Hypersensitivity—Prednisolone—multiple sclerosis	0.00144	0.00159	CcSEcCtD
Roflumilast—Dyspepsia—Betamethasone—multiple sclerosis	0.00144	0.00158	CcSEcCtD
Roflumilast—Dyspepsia—Dexamethasone—multiple sclerosis	0.00144	0.00158	CcSEcCtD
Roflumilast—Urticaria—Triamcinolone—multiple sclerosis	0.00143	0.00158	CcSEcCtD
Roflumilast—Urticaria—Methylprednisolone—multiple sclerosis	0.00143	0.00157	CcSEcCtD
Roflumilast—Dysgeusia—Methotrexate—multiple sclerosis	0.00143	0.00157	CcSEcCtD
Roflumilast—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00142	0.00157	CcSEcCtD
Roflumilast—Decreased appetite—Dexamethasone—multiple sclerosis	0.00142	0.00157	CcSEcCtD
Roflumilast—Decreased appetite—Betamethasone—multiple sclerosis	0.00142	0.00157	CcSEcCtD
Roflumilast—Nausea—Mitoxantrone—multiple sclerosis	0.00142	0.00156	CcSEcCtD
Roflumilast—Infection—Prednisone—multiple sclerosis	0.00142	0.00156	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00141	0.00155	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00141	0.00155	CcSEcCtD
Roflumilast—Back pain—Methotrexate—multiple sclerosis	0.00141	0.00155	CcSEcCtD
Roflumilast—Fatigue—Dexamethasone—multiple sclerosis	0.00141	0.00155	CcSEcCtD
Roflumilast—Fatigue—Betamethasone—multiple sclerosis	0.00141	0.00155	CcSEcCtD
Roflumilast—Nervous system disorder—Prednisone—multiple sclerosis	0.0014	0.00154	CcSEcCtD
Roflumilast—Skin disorder—Prednisone—multiple sclerosis	0.00138	0.00152	CcSEcCtD
Roflumilast—Ill-defined disorder—Methotrexate—multiple sclerosis	0.00135	0.00149	CcSEcCtD
Roflumilast—Feeling abnormal—Betamethasone—multiple sclerosis	0.00135	0.00148	CcSEcCtD
Roflumilast—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00135	0.00148	CcSEcCtD
Roflumilast—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00134	0.00147	CcSEcCtD
Roflumilast—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00134	0.00147	CcSEcCtD
Roflumilast—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00133	0.00146	CcSEcCtD
Roflumilast—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.00133	0.00146	CcSEcCtD
Roflumilast—Malaise—Methotrexate—multiple sclerosis	0.00132	0.00145	CcSEcCtD
Roflumilast—Vertigo—Methotrexate—multiple sclerosis	0.00131	0.00144	CcSEcCtD
Roflumilast—Urticaria—Betamethasone—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Roflumilast—Urticaria—Dexamethasone—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Roflumilast—Dizziness—Prednisolone—multiple sclerosis	0.0013	0.00143	CcSEcCtD
Roflumilast—Asthenia—Triamcinolone—multiple sclerosis	0.00129	0.00142	CcSEcCtD
Roflumilast—Abdominal pain—Dexamethasone—multiple sclerosis	0.00129	0.00142	CcSEcCtD
Roflumilast—Abdominal pain—Betamethasone—multiple sclerosis	0.00129	0.00142	CcSEcCtD
Roflumilast—Asthenia—Methylprednisolone—multiple sclerosis	0.00129	0.00142	CcSEcCtD
Roflumilast—Insomnia—Prednisone—multiple sclerosis	0.00129	0.00142	CcSEcCtD
Roflumilast—Dyspepsia—Prednisone—multiple sclerosis	0.00125	0.00138	CcSEcCtD
Roflumilast—Myalgia—Methotrexate—multiple sclerosis	0.00124	0.00137	CcSEcCtD
Roflumilast—Decreased appetite—Prednisone—multiple sclerosis	0.00124	0.00136	CcSEcCtD
Roflumilast—Rash—Prednisolone—multiple sclerosis	0.00124	0.00136	CcSEcCtD
Roflumilast—Dermatitis—Prednisolone—multiple sclerosis	0.00124	0.00136	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00123	0.00136	CcSEcCtD
Roflumilast—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00123	0.00135	CcSEcCtD
Roflumilast—Fatigue—Prednisone—multiple sclerosis	0.00123	0.00135	CcSEcCtD
Roflumilast—Headache—Prednisolone—multiple sclerosis	0.00123	0.00135	CcSEcCtD
Roflumilast—Discomfort—Methotrexate—multiple sclerosis	0.00123	0.00135	CcSEcCtD
Roflumilast—Constipation—Prednisone—multiple sclerosis	0.00122	0.00134	CcSEcCtD
Roflumilast—Dizziness—Triamcinolone—multiple sclerosis	0.00119	0.00131	CcSEcCtD
Roflumilast—Dizziness—Methylprednisolone—multiple sclerosis	0.00119	0.00131	CcSEcCtD
Roflumilast—Infection—Methotrexate—multiple sclerosis	0.00118	0.0013	CcSEcCtD
Roflumilast—Feeling abnormal—Prednisone—multiple sclerosis	0.00117	0.00129	CcSEcCtD
Roflumilast—Asthenia—Dexamethasone—multiple sclerosis	0.00117	0.00129	CcSEcCtD
Roflumilast—Asthenia—Betamethasone—multiple sclerosis	0.00117	0.00129	CcSEcCtD
Roflumilast—Nervous system disorder—Methotrexate—multiple sclerosis	0.00117	0.00129	CcSEcCtD
Roflumilast—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00117	0.00128	CcSEcCtD
Roflumilast—Nausea—Prednisolone—multiple sclerosis	0.00116	0.00128	CcSEcCtD
Roflumilast—Skin disorder—Methotrexate—multiple sclerosis	0.00116	0.00127	CcSEcCtD
Roflumilast—Vomiting—Triamcinolone—multiple sclerosis	0.00115	0.00126	CcSEcCtD
Roflumilast—Vomiting—Methylprednisolone—multiple sclerosis	0.00114	0.00126	CcSEcCtD
Roflumilast—Rash—Triamcinolone—multiple sclerosis	0.00114	0.00125	CcSEcCtD
Roflumilast—Dermatitis—Triamcinolone—multiple sclerosis	0.00114	0.00125	CcSEcCtD
Roflumilast—Rash—Methylprednisolone—multiple sclerosis	0.00113	0.00125	CcSEcCtD
Roflumilast—Dermatitis—Methylprednisolone—multiple sclerosis	0.00113	0.00125	CcSEcCtD
Roflumilast—Urticaria—Prednisone—multiple sclerosis	0.00113	0.00125	CcSEcCtD
Roflumilast—Headache—Triamcinolone—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Roflumilast—Headache—Methylprednisolone—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Roflumilast—Abdominal pain—Prednisone—multiple sclerosis	0.00113	0.00124	CcSEcCtD
Roflumilast—Diarrhoea—Betamethasone—multiple sclerosis	0.00112	0.00123	CcSEcCtD
Roflumilast—Diarrhoea—Dexamethasone—multiple sclerosis	0.00112	0.00123	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.00108	0.00119	CcSEcCtD
Roflumilast—Dizziness—Betamethasone—multiple sclerosis	0.00108	0.00119	CcSEcCtD
Roflumilast—Dizziness—Dexamethasone—multiple sclerosis	0.00108	0.00119	CcSEcCtD
Roflumilast—Insomnia—Methotrexate—multiple sclerosis	0.00108	0.00119	CcSEcCtD
Roflumilast—Nausea—Triamcinolone—multiple sclerosis	0.00107	0.00118	CcSEcCtD
Roflumilast—Nausea—Methylprednisolone—multiple sclerosis	0.00107	0.00118	CcSEcCtD
Roflumilast—Hypersensitivity—Prednisone—multiple sclerosis	0.00105	0.00116	CcSEcCtD
Roflumilast—Dyspepsia—Methotrexate—multiple sclerosis	0.00105	0.00115	CcSEcCtD
Roflumilast—Vomiting—Betamethasone—multiple sclerosis	0.00104	0.00114	CcSEcCtD
Roflumilast—Vomiting—Dexamethasone—multiple sclerosis	0.00104	0.00114	CcSEcCtD
Roflumilast—Decreased appetite—Methotrexate—multiple sclerosis	0.00104	0.00114	CcSEcCtD
Roflumilast—Rash—Dexamethasone—multiple sclerosis	0.00103	0.00114	CcSEcCtD
Roflumilast—Rash—Betamethasone—multiple sclerosis	0.00103	0.00114	CcSEcCtD
Roflumilast—Dermatitis—Betamethasone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Roflumilast—Dermatitis—Dexamethasone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Roflumilast—Fatigue—Methotrexate—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Roflumilast—Headache—Dexamethasone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Roflumilast—Headache—Betamethasone—multiple sclerosis	0.00103	0.00113	CcSEcCtD
Roflumilast—Asthenia—Prednisone—multiple sclerosis	0.00102	0.00112	CcSEcCtD
Roflumilast—Feeling abnormal—Methotrexate—multiple sclerosis	0.000981	0.00108	CcSEcCtD
Roflumilast—Diarrhoea—Prednisone—multiple sclerosis	0.000975	0.00107	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000974	0.00107	CcSEcCtD
Roflumilast—Nausea—Betamethasone—multiple sclerosis	0.000972	0.00107	CcSEcCtD
Roflumilast—Nausea—Dexamethasone—multiple sclerosis	0.000972	0.00107	CcSEcCtD
Roflumilast—Urticaria—Methotrexate—multiple sclerosis	0.000946	0.00104	CcSEcCtD
Roflumilast—Dizziness—Prednisone—multiple sclerosis	0.000942	0.00104	CcSEcCtD
Roflumilast—Abdominal pain—Methotrexate—multiple sclerosis	0.000941	0.00104	CcSEcCtD
Roflumilast—Vomiting—Prednisone—multiple sclerosis	0.000906	0.000997	CcSEcCtD
Roflumilast—Rash—Prednisone—multiple sclerosis	0.000898	0.000989	CcSEcCtD
Roflumilast—Dermatitis—Prednisone—multiple sclerosis	0.000898	0.000988	CcSEcCtD
Roflumilast—Headache—Prednisone—multiple sclerosis	0.000893	0.000982	CcSEcCtD
Roflumilast—Hypersensitivity—Methotrexate—multiple sclerosis	0.000877	0.000965	CcSEcCtD
Roflumilast—Asthenia—Methotrexate—multiple sclerosis	0.000854	0.00094	CcSEcCtD
Roflumilast—Nausea—Prednisone—multiple sclerosis	0.000846	0.000931	CcSEcCtD
Roflumilast—Diarrhoea—Methotrexate—multiple sclerosis	0.000815	0.000897	CcSEcCtD
Roflumilast—Dizziness—Methotrexate—multiple sclerosis	0.000787	0.000867	CcSEcCtD
Roflumilast—Vomiting—Methotrexate—multiple sclerosis	0.000757	0.000833	CcSEcCtD
Roflumilast—Rash—Methotrexate—multiple sclerosis	0.000751	0.000826	CcSEcCtD
Roflumilast—Dermatitis—Methotrexate—multiple sclerosis	0.00075	0.000825	CcSEcCtD
Roflumilast—Headache—Methotrexate—multiple sclerosis	0.000746	0.000821	CcSEcCtD
Roflumilast—Nausea—Methotrexate—multiple sclerosis	0.000707	0.000778	CcSEcCtD
Roflumilast—PDE4D—Signaling by GPCR—GPR65—multiple sclerosis	0.000186	0.00551	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—IL1B—multiple sclerosis	0.000184	0.00545	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—GPR65—multiple sclerosis	0.00018	0.00534	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LINGO1—multiple sclerosis	0.00018	0.00533	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TAGAP—multiple sclerosis	0.000179	0.00531	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000178	0.00528	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CCR1—multiple sclerosis	0.000178	0.00528	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—GPR65—multiple sclerosis	0.000177	0.00524	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—RGS1—multiple sclerosis	0.000173	0.00512	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LINGO1—multiple sclerosis	0.000171	0.00507	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCL13—multiple sclerosis	0.00017	0.00504	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCR1—multiple sclerosis	0.00017	0.00504	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CCR1—multiple sclerosis	0.000165	0.00489	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000165	0.00489	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—GPR65—multiple sclerosis	0.000164	0.00485	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—IL1B—multiple sclerosis	0.000162	0.0048	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCR1—multiple sclerosis	0.000162	0.0048	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCL13—multiple sclerosis	0.000162	0.0048	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LINGO1—multiple sclerosis	0.000158	0.00469	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—S1PR1—multiple sclerosis	0.000157	0.00464	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TAGAP—multiple sclerosis	0.000156	0.00462	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GPC5—multiple sclerosis	0.000152	0.00451	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCR1—multiple sclerosis	0.00015	0.00444	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCL13—multiple sclerosis	0.00015	0.00444	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TAGAP—multiple sclerosis	0.000148	0.0044	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000148	0.00437	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000143	0.00422	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CCL3—multiple sclerosis	0.000139	0.00412	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CCR2—multiple sclerosis	0.000139	0.00411	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TAGAP—multiple sclerosis	0.000137	0.00407	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—S1PR1—multiple sclerosis	0.000136	0.00404	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PTGER4—multiple sclerosis	0.000134	0.00397	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—RGS1—multiple sclerosis	0.000133	0.00394	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GPC5—multiple sclerosis	0.000133	0.00393	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—S1PR1—multiple sclerosis	0.00013	0.00384	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CXCR3—multiple sclerosis	0.000129	0.00383	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000128	0.00381	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CNR1—multiple sclerosis	0.000128	0.00379	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GPC5—multiple sclerosis	0.000126	0.00374	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GPR65—multiple sclerosis	0.000126	0.00374	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CCR2—multiple sclerosis	0.000126	0.00373	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000124	0.00368	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000122	0.00362	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCL3—multiple sclerosis	0.000121	0.00359	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CCR2—multiple sclerosis	0.000121	0.00358	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—S1PR1—multiple sclerosis	0.00012	0.00356	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000118	0.0035	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GPC5—multiple sclerosis	0.000117	0.00346	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PTGER4—multiple sclerosis	0.000117	0.00346	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CNR1—multiple sclerosis	0.000116	0.00344	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RGS1—multiple sclerosis	0.000116	0.00343	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCR1—multiple sclerosis	0.000115	0.00342	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCL13—multiple sclerosis	0.000115	0.00342	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCL3—multiple sclerosis	0.000115	0.00342	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000115	0.00341	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CCR2—multiple sclerosis	0.000115	0.0034	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000113	0.00335	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCR3—multiple sclerosis	0.000113	0.00334	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CNR1—multiple sclerosis	0.000111	0.0033	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PTGER4—multiple sclerosis	0.000111	0.00329	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RGS1—multiple sclerosis	0.00011	0.00327	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GPR65—multiple sclerosis	0.00011	0.00325	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCR2—multiple sclerosis	0.00011	0.00325	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000109	0.00324	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—IL6—multiple sclerosis	0.000108	0.00319	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCR3—multiple sclerosis	0.000107	0.00318	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCL3—multiple sclerosis	0.000107	0.00316	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CCR2—multiple sclerosis	0.000106	0.00315	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CNR1—multiple sclerosis	0.000106	0.00314	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CXCL10—multiple sclerosis	0.000105	0.0031	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GPR65—multiple sclerosis	0.000105	0.0031	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCR2—multiple sclerosis	0.000104	0.00309	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PTGER4—multiple sclerosis	0.000103	0.00304	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RGS1—multiple sclerosis	0.000102	0.00302	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CNR1—multiple sclerosis	0.000101	0.003	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCR1—multiple sclerosis	0.0001	0.00298	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCL13—multiple sclerosis	0.0001	0.00298	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CXCL10—multiple sclerosis	0.0001	0.00297	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCR3—multiple sclerosis	9.92e-05	0.00294	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CCL5—multiple sclerosis	9.92e-05	0.00294	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CNR1—multiple sclerosis	9.81e-05	0.00291	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GPR65—multiple sclerosis	9.68e-05	0.00287	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCR2—multiple sclerosis	9.65e-05	0.00286	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CNR1—multiple sclerosis	9.63e-05	0.00285	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCL13—multiple sclerosis	9.56e-05	0.00283	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCR1—multiple sclerosis	9.56e-05	0.00283	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CXCL10—multiple sclerosis	9.55e-05	0.00283	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—multiple sclerosis	9.49e-05	0.00281	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCL10—multiple sclerosis	9.11e-05	0.0027	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CCL5—multiple sclerosis	9.01e-05	0.00267	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CCR5—multiple sclerosis	8.93e-05	0.00265	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CNR1—multiple sclerosis	8.91e-05	0.00264	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCL13—multiple sclerosis	8.85e-05	0.00262	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCR1—multiple sclerosis	8.85e-05	0.00262	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCL10—multiple sclerosis	8.83e-05	0.00262	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—IL2RA—multiple sclerosis	8.81e-05	0.00261	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCL10—multiple sclerosis	8.67e-05	0.00257	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CCL5—multiple sclerosis	8.63e-05	0.00256	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCL3—multiple sclerosis	8.22e-05	0.00244	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CCL5—multiple sclerosis	8.22e-05	0.00243	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CCR5—multiple sclerosis	8.11e-05	0.0024	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCL10—multiple sclerosis	8.02e-05	0.00238	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL2RA—multiple sclerosis	8e-05	0.00237	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTGER4—multiple sclerosis	7.92e-05	0.00234	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCL5—multiple sclerosis	7.84e-05	0.00232	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PGR—multiple sclerosis	7.8e-05	0.00231	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CCR5—multiple sclerosis	7.78e-05	0.0023	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—IL2RA—multiple sclerosis	7.67e-05	0.00227	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCR3—multiple sclerosis	7.65e-05	0.00226	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CCL5—multiple sclerosis	7.6e-05	0.00225	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CD28—multiple sclerosis	7.57e-05	0.00224	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCL5—multiple sclerosis	7.46e-05	0.00221	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCR2—multiple sclerosis	7.44e-05	0.0022	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CCR5—multiple sclerosis	7.4e-05	0.00219	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—IL2RA—multiple sclerosis	7.3e-05	0.00216	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCL3—multiple sclerosis	7.16e-05	0.00212	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCR5—multiple sclerosis	7.06e-05	0.00209	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—POMC—multiple sclerosis	6.98e-05	0.00207	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL2RA—multiple sclerosis	6.96e-05	0.00206	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCL5—multiple sclerosis	6.9e-05	0.00205	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTGER4—multiple sclerosis	6.89e-05	0.00204	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CNR1—multiple sclerosis	6.86e-05	0.00203	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CCR5—multiple sclerosis	6.85e-05	0.00203	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCL3—multiple sclerosis	6.81e-05	0.00202	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PGR—multiple sclerosis	6.79e-05	0.00201	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—IL2RA—multiple sclerosis	6.75e-05	0.002	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCR5—multiple sclerosis	6.72e-05	0.00199	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCR3—multiple sclerosis	6.66e-05	0.00197	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL2RA—multiple sclerosis	6.63e-05	0.00196	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CD28—multiple sclerosis	6.59e-05	0.00195	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTGER4—multiple sclerosis	6.56e-05	0.00194	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCR2—multiple sclerosis	6.47e-05	0.00192	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PGR—multiple sclerosis	6.46e-05	0.00191	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—POMC—multiple sclerosis	6.34e-05	0.00188	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCR3—multiple sclerosis	6.34e-05	0.00188	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCL3—multiple sclerosis	6.31e-05	0.00187	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CD28—multiple sclerosis	6.28e-05	0.00186	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCR5—multiple sclerosis	6.22e-05	0.00184	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CCL2—multiple sclerosis	6.2e-05	0.00184	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCL10—multiple sclerosis	6.18e-05	0.00183	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCR2—multiple sclerosis	6.16e-05	0.00183	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL2RA—multiple sclerosis	6.13e-05	0.00182	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—POMC—multiple sclerosis	6.08e-05	0.0018	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTGER4—multiple sclerosis	6.07e-05	0.0018	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PGR—multiple sclerosis	5.98e-05	0.00177	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CNR1—multiple sclerosis	5.98e-05	0.00177	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCR3—multiple sclerosis	5.86e-05	0.00174	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CD28—multiple sclerosis	5.81e-05	0.00172	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—POMC—multiple sclerosis	5.79e-05	0.00171	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCR2—multiple sclerosis	5.7e-05	0.00169	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CNR1—multiple sclerosis	5.69e-05	0.00168	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—TYK2—multiple sclerosis	5.63e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—POMC—multiple sclerosis	5.52e-05	0.00164	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CD86—multiple sclerosis	5.4e-05	0.0016	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCL2—multiple sclerosis	5.4e-05	0.0016	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCL10—multiple sclerosis	5.38e-05	0.00159	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—POMC—multiple sclerosis	5.35e-05	0.00159	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCL5—multiple sclerosis	5.32e-05	0.00158	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CNR1—multiple sclerosis	5.26e-05	0.00156	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—POMC—multiple sclerosis	5.25e-05	0.00156	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—IL2—multiple sclerosis	5.16e-05	0.00153	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCL2—multiple sclerosis	5.14e-05	0.00152	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCL10—multiple sclerosis	5.12e-05	0.00152	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SPP1—multiple sclerosis	4.93e-05	0.00146	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—TYK2—multiple sclerosis	4.9e-05	0.00145	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—POMC—multiple sclerosis	4.86e-05	0.00144	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCR5—multiple sclerosis	4.79e-05	0.00142	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCL2—multiple sclerosis	4.76e-05	0.00141	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCL10—multiple sclerosis	4.74e-05	0.0014	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL2RA—multiple sclerosis	4.72e-05	0.0014	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CD86—multiple sclerosis	4.7e-05	0.00139	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL2—multiple sclerosis	4.69e-05	0.00139	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—TYK2—multiple sclerosis	4.67e-05	0.00138	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCL5—multiple sclerosis	4.63e-05	0.00137	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—IL2—multiple sclerosis	4.49e-05	0.00133	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CD86—multiple sclerosis	4.48e-05	0.00133	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCL5—multiple sclerosis	4.41e-05	0.00131	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APOE—multiple sclerosis	4.36e-05	0.00129	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—TYK2—multiple sclerosis	4.32e-05	0.00128	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SPP1—multiple sclerosis	4.29e-05	0.00127	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—IL2—multiple sclerosis	4.28e-05	0.00127	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCR5—multiple sclerosis	4.17e-05	0.00124	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CD86—multiple sclerosis	4.14e-05	0.00123	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL2RA—multiple sclerosis	4.11e-05	0.00122	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SPP1—multiple sclerosis	4.08e-05	0.00121	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL2—multiple sclerosis	4.08e-05	0.00121	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCL5—multiple sclerosis	4.08e-05	0.00121	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCR5—multiple sclerosis	3.97e-05	0.00118	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—IL2—multiple sclerosis	3.96e-05	0.00117	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CD80—multiple sclerosis	3.94e-05	0.00117	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL2RA—multiple sclerosis	3.91e-05	0.00116	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL2—multiple sclerosis	3.88e-05	0.00115	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APOE—multiple sclerosis	3.8e-05	0.00112	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SPP1—multiple sclerosis	3.78e-05	0.00112	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—POMC—multiple sclerosis	3.75e-05	0.00111	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCR5—multiple sclerosis	3.67e-05	0.00109	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCL2—multiple sclerosis	3.67e-05	0.00109	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL2RA—multiple sclerosis	3.62e-05	0.00107	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APOE—multiple sclerosis	3.61e-05	0.00107	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL2—multiple sclerosis	3.59e-05	0.00106	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—MAPK1—multiple sclerosis	3.59e-05	0.00106	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CD80—multiple sclerosis	3.43e-05	0.00102	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APOE—multiple sclerosis	3.34e-05	0.00099	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TYK2—multiple sclerosis	3.33e-05	0.000986	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CD80—multiple sclerosis	3.27e-05	0.000968	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—POMC—multiple sclerosis	3.26e-05	0.000966	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCL2—multiple sclerosis	3.19e-05	0.000945	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—MAPK1—multiple sclerosis	3.12e-05	0.000925	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—POMC—multiple sclerosis	3.1e-05	0.000919	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCL2—multiple sclerosis	3.04e-05	0.0009	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CD80—multiple sclerosis	3.02e-05	0.000895	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—MAPK1—multiple sclerosis	2.97e-05	0.00088	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TYK2—multiple sclerosis	2.9e-05	0.000858	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—POMC—multiple sclerosis	2.87e-05	0.000851	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCL2—multiple sclerosis	2.81e-05	0.000832	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL2—multiple sclerosis	2.77e-05	0.00082	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TYK2—multiple sclerosis	2.76e-05	0.000817	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—multiple sclerosis	2.76e-05	0.000816	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAPK1—multiple sclerosis	2.75e-05	0.000814	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP9—multiple sclerosis	2.62e-05	0.000776	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TYK2—multiple sclerosis	2.55e-05	0.000756	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL2—multiple sclerosis	2.41e-05	0.000714	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—multiple sclerosis	2.4e-05	0.000711	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—STAT3—multiple sclerosis	2.33e-05	0.00069	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL2—multiple sclerosis	2.29e-05	0.00068	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—multiple sclerosis	2.28e-05	0.000676	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP9—multiple sclerosis	2.28e-05	0.000676	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP9—multiple sclerosis	2.17e-05	0.000643	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MYC—multiple sclerosis	2.17e-05	0.000641	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFB1—multiple sclerosis	2.16e-05	0.00064	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL2—multiple sclerosis	2.12e-05	0.000629	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK1—multiple sclerosis	2.12e-05	0.000627	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—multiple sclerosis	2.11e-05	0.000626	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—STAT3—multiple sclerosis	2.03e-05	0.000601	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP9—multiple sclerosis	2.01e-05	0.000595	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—STAT3—multiple sclerosis	1.93e-05	0.000572	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MYC—multiple sclerosis	1.89e-05	0.000558	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFB1—multiple sclerosis	1.88e-05	0.000557	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK1—multiple sclerosis	1.84e-05	0.000546	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MYC—multiple sclerosis	1.79e-05	0.000531	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFB1—multiple sclerosis	1.79e-05	0.00053	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—STAT3—multiple sclerosis	1.79e-05	0.000529	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK1—multiple sclerosis	1.76e-05	0.00052	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MYC—multiple sclerosis	1.66e-05	0.000492	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFB1—multiple sclerosis	1.66e-05	0.000491	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—multiple sclerosis	1.63e-05	0.000482	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK1—multiple sclerosis	1.62e-05	0.000481	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—multiple sclerosis	1.42e-05	0.00042	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—multiple sclerosis	1.35e-05	0.0004	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—multiple sclerosis	1.25e-05	0.00037	CbGpPWpGaD
